Safety of Switching to Migalastat From Enzyme Replacement Therapy in Fabry Disease: Experience From the Phase 3 ATTRACT Study

American Journal of Medical Genetics, Part A- United States

doi 10.1002/ajmg.a.61105

Full Text

Abstract

Available in

Categories

Date

March 28, 2019

Authors

Derralynn A. Hughes

Kathleen Nicholls

Gere Sunder‐Plassmann

Ulla Feldt‐Rasmussen

Raphael Schiffmann

Robert Giugliani

Jeffrey P. Castelli

Daniel G. Bichet

Publisher

Wiley

Related search

Renal Aspects and Enzyme Replacement Therapy of Fabry Disease

English

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN

English

Effects of Enzyme Replacement Therapy in Fabry Disease—A Comprehensive Review of the Medical Literature

Genetics in Medicine

English

Efficacy and Safety of Migalastat in a Japanese Population: A Subgroup Analysis of the ATTRACT Study

Clinical and Experimental Nephrology

English

Do We Need More Intensive Enzyme Replacement Therapy for Anderson-Fabry Disease?

Medical Hypotheses

English

Modeling the Effect of Enzyme Replacement Therapy on Life-Threatening Complications in Patients With Fabry Disease

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

English

Limited Effects of Long-Term Enzyme Replacement Therapy on the Cardiac Conduction System in Fabry Disease

Journal of Cardiology Cases

Cardiovascular Medicine

English

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Prominent Regression of Corneal Deposits in Fabry Disease 16 Years After Initiation of Enzyme Replacement Therapy

Acta Ophthalmologica

English